TY - JOUR
T1 - Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer
T2 - A systematic review
AU - Vollenbrock, Sophie E.
AU - Voncken, Francine E. M.
AU - Bartels, Lambertus W.
AU - Beets-Tan, Regina G. H.
AU - Bartels-Rutten, Annemarieke
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - Purpose: The aim was to perform a systematic review on the value of diffusion-weighted MRI (DW-MRI) with apparent diffusion coefficient (ADC) mapping in the prediction and assessment of response to chemo- and/or radiotherapy in oesophageal cancer.Materials and methods: A systematic search was performed on Pubmed, Embase, Medline and Cochrane databases. Studies that evaluated the ADC for response evaluation before, during or after chemo- and/or radiotherapy were included. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was used to assess the quality of the included studies.Results: Fourteen studies, comprising 516 patients, in which the response to treatment in oesophageal cancer was evaluated on ADC maps were included. Acquisition parameter settings for DW-MRI and ROI placement varied substantially. The reference standard was RECIST or endoscopic assessment in eight non-surgery studies and histopathology after surgery in six studies. A high pre-treatment ADC significantly correlated with good response in three out of 12 studies; conversely, one study reported a significantly higher pre-treatment ADC in poor responders. In five out of eight studies good responders showed a significantly larger relative increase in ADC two weeks after the onset of treatment (range 23-59%) than poor responders (range 1.5-17%). After chemo- and/or radiotherapy ADC results varied considerably, amongst others due to large variation in the interval between completion of therapy and DW-MRI.Conclusion: DW-MRI for response evaluation to chemo- and/or radiotherapy in oesophageal cancer shows variable methods and results. A large relative ADC increase after two weeks of treatment seems most predictive for good response. (C) 2019 Elsevier B.V. All rights reserved.
AB - Purpose: The aim was to perform a systematic review on the value of diffusion-weighted MRI (DW-MRI) with apparent diffusion coefficient (ADC) mapping in the prediction and assessment of response to chemo- and/or radiotherapy in oesophageal cancer.Materials and methods: A systematic search was performed on Pubmed, Embase, Medline and Cochrane databases. Studies that evaluated the ADC for response evaluation before, during or after chemo- and/or radiotherapy were included. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was used to assess the quality of the included studies.Results: Fourteen studies, comprising 516 patients, in which the response to treatment in oesophageal cancer was evaluated on ADC maps were included. Acquisition parameter settings for DW-MRI and ROI placement varied substantially. The reference standard was RECIST or endoscopic assessment in eight non-surgery studies and histopathology after surgery in six studies. A high pre-treatment ADC significantly correlated with good response in three out of 12 studies; conversely, one study reported a significantly higher pre-treatment ADC in poor responders. In five out of eight studies good responders showed a significantly larger relative increase in ADC two weeks after the onset of treatment (range 23-59%) than poor responders (range 1.5-17%). After chemo- and/or radiotherapy ADC results varied considerably, amongst others due to large variation in the interval between completion of therapy and DW-MRI.Conclusion: DW-MRI for response evaluation to chemo- and/or radiotherapy in oesophageal cancer shows variable methods and results. A large relative ADC increase after two weeks of treatment seems most predictive for good response. (C) 2019 Elsevier B.V. All rights reserved.
KW - MRI
KW - Oesophageal cancer
KW - Apparent diffusion coefficient
KW - Response
KW - SQUAMOUS-CELL CARCINOMA
KW - NEOADJUVANT CHEMORADIOTHERAPY
KW - F-18-FDG PET
KW - PREOPERATIVE CHEMORADIOTHERAPY
KW - DIAGNOSTIC PERFORMANCE
KW - TUMOR-REGRESSION
KW - COEFFICIENT
KW - ADENOCARCINOMA
KW - EVALUATE
KW - VALUES
U2 - 10.1016/j.radonc.2019.07.006
DO - 10.1016/j.radonc.2019.07.006
M3 - (Systematic) Review article
C2 - 31431376
SN - 0167-8140
VL - 142
SP - 17
EP - 26
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -